Seawolf Therapeutics raises $100M
Seawolf Therapeutics announced a Series A round of $100M on 16 November 2026. The company operates in HealthTech and is based in United States. It was founded by Elizabeth Alcamo, President & CEO. Announced 2 days ago.
Founder
Elizabeth Alcamo
President & CEO, Seawolf Therapeutics
Outreach angles
- -Elizabeth Alcamo leads Seawolf as president and CEO as it emerges from stealth to develop redosable LNP-based DNA medicines.
- -Alcamo says the Sanofi collaboration and investor syndicate position Seawolf to advance its lead metabolic disease programme.
- -The $100M across seed and Series A came alongside a Sanofi licence deal worth up to $1.2 billion in milestones plus royalties.
Signals
Series ADeep TechHealthcareRegulated Industry
Round details
Company: Seawolf Therapeutics
Domain: seawolftx.com
Amount: $100M
Stage: Series A
Industry: HealthTech
Country: United States
Announced: 16 November 2026
Other HealthTech raises
Recently funded in United States